Therapeutics Initiative |

15 Feb Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Posted at 10:00h in PharmacoEpidemiology 0 Comments

Anat Fisher, Jason D. Kim, Colin R. Dormuth CMAJ Open February 15, 2022 10 (1) E109-E118; DOI: 10.9778/cmajo.20200319 Abstract Background: In 2019, British Columbia’s public drug plan, PharmaCare, was the first in Canada to implement a nonmedical switching...

11 Nov [123] Biosimilars or Biologics: What’s the difference?

Posted at 13:28h in Therapeutics Letter 4 Comments

According to Greek mythology, the Chimera was a fire-breathing hybrid creature composed of parts of more than one animal, usually depicted as a lion with the head of a goat protruding from its back. Recombinant...

21 Feb A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia

Posted at 18:22h in PharmacoEpidemiology 0 Comments

Dormuth CR, Fisher A, Carney G Pharmacoepidemiology & Drug Safety. 2020 https://doi.org/10.1002/pds.4957 Abstract Purpose: To describe a rapid monitoring plan to assess the impacts of a shift in drug coverage for biosimilar drugs in British Columbia following the introduction...

infliximab Tag

15 Feb Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

11 Nov [123] Biosimilars or Biologics: What’s the difference?

21 Feb A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia

Contact

Subscribe for Updates